JP2009521206A5 - - Google Patents

Info

Publication number

JP2009521206A5

JP2009521206A5 JP2008508006A JP2008508006A JP2009521206A5 JP 2009521206 A5 JP2009521206 A5 JP 2009521206A5 JP 2008508006 A JP2008508006 A JP 2008508006A JP 2008508006 A JP2008508006 A JP 2008508006A JP 2009521206 A5 JP2009521206 A5 JP 2009521206A5

Authority

JP

Japan

Prior art keywords

antibody

present

further embodiment

receptor alpha

folate receptor

Prior art date

2006-04-24

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 102000010451 Folate receptor alpha Human genes 0.000 claims description 28
• 108050001931 Folate receptor alpha Proteins 0.000 claims description 28
• 239000008194 pharmaceutical composition Substances 0.000 claims description 9
• 206010028980 Neoplasm Diseases 0.000 claims description 5
• 230000001419 dependent effect Effects 0.000 claims description 3
• 230000001939 inductive effect Effects 0.000 claims description 3
• 239000000203 mixture Substances 0.000 claims description 3
• 201000011510 cancer Diseases 0.000 claims 2
• 206010033128 Ovarian cancer Diseases 0.000 claims 1
• 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
• 229930012538 Paclitaxel Natural products 0.000 claims 1
• 150000001720 carbohydrates Chemical class 0.000 claims 1
• 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 1
• 229960001592 paclitaxel Drugs 0.000 claims 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
• 210000004027 cell Anatomy 0.000 description 36
• 238000000034 method Methods 0.000 description 35
• 239000000126 substance Substances 0.000 description 16
• 230000000973 chemotherapeutic effect Effects 0.000 description 13
• 239000002157 polynucleotide Substances 0.000 description 11
• 102000040430 polynucleotide Human genes 0.000 description 11
• 108091033319 polynucleotide Proteins 0.000 description 11
• 230000003432 anti-folate effect Effects 0.000 description 10
• 229940127074 antifolate Drugs 0.000 description 10
• 239000004052 folic acid antagonist Substances 0.000 description 10
• 102000005962 receptors Human genes 0.000 description 10
• 108020003175 receptors Proteins 0.000 description 10
• 230000012010 growth Effects 0.000 description 9
• 230000002401 inhibitory effect Effects 0.000 description 7
• 230000000694 effects Effects 0.000 description 6
• 239000012642 immune effector Substances 0.000 description 6
• 229940121354 immunomodulator Drugs 0.000 description 6
• 239000000032 diagnostic agent Substances 0.000 description 4
• 229940039227 diagnostic agent Drugs 0.000 description 4
• 102000006815 folate receptor Human genes 0.000 description 4
• 108020005243 folate receptor Proteins 0.000 description 4
• 210000004962 mammalian cell Anatomy 0.000 description 3
• 238000011084 recovery Methods 0.000 description 3
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
• 125000003275 alpha amino acid group Chemical group 0.000 description 2
• 238000012258 culturing Methods 0.000 description 2
• 239000000824 cytostatic agent Substances 0.000 description 2
• 230000001085 cytostatic effect Effects 0.000 description 2
• 231100000433 cytotoxic Toxicity 0.000 description 2
• 239000002254 cytotoxic agent Substances 0.000 description 2
• 229940127089 cytotoxic agent Drugs 0.000 description 2
• 230000001472 cytotoxic effect Effects 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 210000004408 hybridoma Anatomy 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 239000002773 nucleotide Substances 0.000 description 2
• 125000003729 nucleotide group Chemical group 0.000 description 2
• 239000000825 pharmaceutical preparation Substances 0.000 description 2
• 229940127557 pharmaceutical product Drugs 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 1
• 238000009175 antibody therapy Methods 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 201000010099 disease Diseases 0.000 description 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 230000004584 weight gain Effects 0.000 description 1
• 235000019786 weight gain Nutrition 0.000 description 1